Tags

Type your tag names separated by a space and hit enter

Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther 2002; 16(8):1481-90AP

Abstract

AIM

The effect of ABT-229, a new macrolide with no antibacterial activity, on gastro-oesophageal reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease was investigated.

METHODS

Twenty-one patients were treated with a placebo and ABT-229 (2.5, 5 or 10 mg b.d.) in a randomized, incomplete crossover study design. Ambulatory 24-h pH manometry was performed and gastric emptying was assessed by the 13C-octanoic acid breath test on the seventh day of treatment.

RESULTS

A significant decrease was found in the mean (+/- s.e.) percentage of reflux time (intra-oesophageal pH < 4) for ABT-229 5 mg b.d. and 10 mg b.d., but not for 2.5 mg b.d., compared with placebo. For ABT-229 5 mg, it was 8.5 +/- 0.5% vs. 10.7 +/- 0.7% (P < 0.038) and, for ABT-229 10 mg, it was 6.6 +/- 0.5% vs. 8.4 +/- 0.5% (P < 0.019). There were no significant differences in any of the analysed manometric parameters. In addition, the gastric half-emptying time for all doses of ABT-229 did not differ significantly from that after placebo.

CONCLUSIONS

ABT-229 is able to reduce slightly, but significantly, acid reflux in patients with gastro-oesophageal reflux disease. This effect does not appear to be due to a measurable improvement in oesophageal motility or gastric emptying.

Authors+Show Affiliations

Gastrointestinal Unit. Inselspital, University Hospital of Berne, Switzerland. inauen@swissonline.chNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12182748

Citation

Netzer, P, et al. "Effects of ABT-229, a Motilin Agonist, On Acid Reflux, Oesophageal Motility and Gastric Emptying in Patients With Gastro-oesophageal Reflux Disease." Alimentary Pharmacology & Therapeutics, vol. 16, no. 8, 2002, pp. 1481-90.
Netzer P, Schmitt B, Inauen W. Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(8):1481-90.
Netzer, P., Schmitt, B., & Inauen, W. (2002). Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 16(8), pp. 1481-90.
Netzer P, Schmitt B, Inauen W. Effects of ABT-229, a Motilin Agonist, On Acid Reflux, Oesophageal Motility and Gastric Emptying in Patients With Gastro-oesophageal Reflux Disease. Aliment Pharmacol Ther. 2002;16(8):1481-90. PubMed PMID: 12182748.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of ABT-229, a motilin agonist, on acid reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease. AU - Netzer,P, AU - Schmitt,B, AU - Inauen,W, PY - 2002/8/17/pubmed PY - 2003/2/15/medline PY - 2002/8/17/entrez SP - 1481 EP - 90 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 16 IS - 8 N2 - AIM: The effect of ABT-229, a new macrolide with no antibacterial activity, on gastro-oesophageal reflux, oesophageal motility and gastric emptying in patients with gastro-oesophageal reflux disease was investigated. METHODS: Twenty-one patients were treated with a placebo and ABT-229 (2.5, 5 or 10 mg b.d.) in a randomized, incomplete crossover study design. Ambulatory 24-h pH manometry was performed and gastric emptying was assessed by the 13C-octanoic acid breath test on the seventh day of treatment. RESULTS: A significant decrease was found in the mean (+/- s.e.) percentage of reflux time (intra-oesophageal pH < 4) for ABT-229 5 mg b.d. and 10 mg b.d., but not for 2.5 mg b.d., compared with placebo. For ABT-229 5 mg, it was 8.5 +/- 0.5% vs. 10.7 +/- 0.7% (P < 0.038) and, for ABT-229 10 mg, it was 6.6 +/- 0.5% vs. 8.4 +/- 0.5% (P < 0.019). There were no significant differences in any of the analysed manometric parameters. In addition, the gastric half-emptying time for all doses of ABT-229 did not differ significantly from that after placebo. CONCLUSIONS: ABT-229 is able to reduce slightly, but significantly, acid reflux in patients with gastro-oesophageal reflux disease. This effect does not appear to be due to a measurable improvement in oesophageal motility or gastric emptying. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/12182748/Effects_of_ABT_229_a_motilin_agonist_on_acid_reflux_oesophageal_motility_and_gastric_emptying_in_patients_with_gastro_oesophageal_reflux_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0269-2813&amp;date=2002&amp;volume=16&amp;issue=8&amp;spage=1481 DB - PRIME DP - Unbound Medicine ER -